{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:46:48Z","timestamp":1792075608223,"version":"4.4.0"},"reference-count":23,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,14]]},"DOI":"10.31744\/einstein_journal\/2026ao1654","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:15:44Z","timestamp":1792073744000},"source":"Crossref","is-referenced-by-count":0,"title":["Differences in the clinical profile between isolated lupus anticoagulant and triplepositive antiphospholipid antibody profiles in primary antiphospholipid syndrome"],"prefix":"10.31744","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9848-9093","authenticated-orcid":false,"given":"Bruno Verza","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1017","authenticated-orcid":false,"given":"Flavio","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-8834","authenticated-orcid":false,"given":"Gustavo Guimar\u00e3es Moreira","family":"Balbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-1808","authenticated-orcid":false,"given":"Danieli Castro Oliveira","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"10","key":"key20261015141536_B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","unstructured":"1 Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR\/EULAR APS Classification Criteria Collaborators. The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023;75(10):1687-702.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"key20261015141536_B2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","unstructured":"2 Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.","journal-title":"J Thromb Haemost"},{"issue":"17","key":"key20261015141536_B3","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","unstructured":"3 Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714-8.","journal-title":"Blood"},{"issue":"2","key":"key20261015141536_B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","unstructured":"4 Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-42.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"key20261015141536_B5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the Global Anti-Phospholipid Syndrome Score","volume":"52","author":"Sciascia","year":"2013","unstructured":"5 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013;52(8):1397-403.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"key20261015141536_B6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort","volume":"49","author":"Radin","year":"2019","unstructured":"6 Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jes\u00fas G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum. 2019;49(3):464-8.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"key20261015141536_B7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002534","article-title":"Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study","volume":"9","author":"Laurent","year":"2023","unstructured":"7 Laurent C, Ricard L, Nguyen Y, Boffa JJ, Rondeau E, Gerotziafas G, et al. Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study. RMD Open. 2023; 9(1):e002534.","journal-title":"RMD Open"},{"issue":"5","key":"key20261015141536_B8","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","unstructured":"8 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827-32.","journal-title":"Blood"},{"issue":"2","key":"key20261015141536_B9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.blre.2010.12.001","article-title":"Antiphospholipid antibodies \u2013 we are not quite there yet","volume":"25","author":"Urbanus","year":"2011","unstructured":"9 Urbanus RT, de Groot PG. Antiphospholipid antibodies \u2013 we are not quite there yet. Blood Rev. 2011 Mar;25(2):97-106.","journal-title":"Blood Rev"},{"issue":"22","key":"key20261015141536_B10","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)","volume":"125","author":"Gebhart","year":"2015","unstructured":"10 Gebhart J, Posch F, Koder S, Perkmann T, Quehenberger P, Zoghlami C et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood. 2015;125(22):3477-83.","journal-title":"Blood"},{"issue":"4","key":"key20261015141536_B11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","unstructured":"11 Devreese KM, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(4):809-13.","journal-title":"J Thromb Haemost"},{"issue":"24","key":"key20261015141536_B12","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","unstructured":"12 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-209.","journal-title":"J Am Coll Cardiol"},{"key":"key20261015141536_B13","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"13 American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45 Suppl 1:S17-38.","journal-title":"Diabetes Care"},{"issue":"6","key":"key20261015141536_B14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","unstructured":"14 Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324.","journal-title":"Hypertension"},{"issue":"6","key":"key20261015141536_B15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi","year":"2017","unstructured":"15 Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31(6):406-17.","journal-title":"Blood Rev"},{"issue":"11","key":"key20261015141536_B16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","unstructured":"16 Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998-1005.","journal-title":"Lancet Neurol"},{"issue":"3","key":"key20261015141536_B17","first-page":"382","article-title":"The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome","volume":"31","author":"Hern\u00e1ndez-Molina","year":"2013","unstructured":"17 Hern\u00e1ndez-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol. 2013;31(3):382-8.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"key20261015141536_B18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/M14-2235","article-title":"Predictors of pregnancy outcomes in patients with lupus: a cohort study","volume":"163","author":"Buyon","year":"2015","unstructured":"18 Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153-63.","journal-title":"Ann Intern Med"},{"issue":"3","key":"key20261015141536_B19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.thromres.2008.03.012","article-title":"Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy","volume":"123","author":"Ruffatti","year":"2009","unstructured":"19 Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res. 2009;123(3):482-7.","journal-title":"Thromb Res"},{"issue":"4","key":"key20261015141536_B20","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","unstructured":"20 Kravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev. 2020;19(4):102491.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"key20261015141536_B21","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","unstructured":"21 Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11(10):1927-9.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"key20261015141536_B22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","unstructured":"22 Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"key20261015141536_B23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome","volume":"17","author":"Belizna","year":"2018","unstructured":"23 Belizna C, Pregnolato F, Abad S, Alijotas-Reig J, Amital H, Amoura Z, et al. HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev. 2018;17(12):1153-68.","journal-title":"Autoimmun Rev"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:15:47Z","timestamp":1792073747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/differences-in-the-clinical-profile-between-isolated-lupus-anticoagulant-and-triplepositive-antiphospholipid-antibody-profiles-in-primary-antiphospholipid-syndrome\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"alternative-id":["10.31744\/einstein_journal\/2026AO1654"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2026ao1654","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"eAO1654"}}